SEC Form 4 · accession 0001193125-26-271170
Aura Biosciences, Inc. · AURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sapna Srivastava
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 15, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001501796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 11, 2026 | A | 15,000 | $0.00 | A | 38,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $6.21 | Jun 11, 2026 | A | 30,000 | A | — | Jun 11, 2036 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
- F2This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.